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Introduction
Cancer is set to become a major cause of morbidity 
and mortality in the coming decades in every region of 
the world (Bray et al., 2012). Today, Cancer is the leading 
cause of death in economically developed countries and 
the second leading cause of death in developing countries 
(Jemal et al., 2011). Malignant disorders in hematopoietic 
system include different conditions which some of them 
are related to bone marrow and other may be related to 
lymphatic system. Three main types of blood cancer are 
leukemia, lymphoma myeloma and plasma cell disorders 
(Rodriguez-Abreu et al., 2007).
Leukemia is a metastatic and malignant disease for 
blood-making organs which is resulted due to incomplete 
evolution and problematic proliferation of white blood 
cells (WBCs) and its substrates in blood and bone marrow 
(Howlader N NA, , based on November 2013 SEER data 
submission, posted to the SEER web site, April 2014). 
Leukemia is responsible for 8% of total cancer cases (Zand 
et al., 2010) and involves all age groups with different 
prevalence and incidence rate in Iran and whole the world 
and causes significant death toll and heavy expenses for 
diagnosis and treatment process (Tahmasebi et al., 2006). 
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Abstract
 Background: Leukemia accounts for 8% of total cancer cases and involves all age groups with different 
prevalence and incidence rates in Iran and the entire world and causes a significant death toll and heavy expenses 
for diagnosis and treatment processes. This study was done to evaluate epidemiology and morphology of blood 
cancer during 2003-2008. Materials and Methods: This cross- sectional study was carried out based on re-
analysis of the Cancer Registry Center report of the Health Deputy in Iran during a 6-year period (2003 - 2008). 
Statistical analysis for incidence time trends and morphology change percentage was performed with joinpoint 
regression analysis using the software Joinpoint Regression Program. Results: During the studied years a total of 
18,353 hematopoietic and reticuloendothelial system cancers were recorded. Chi square test showed significant 
difference between sex and morphological types of blood cancer (P-value<0.001). Joinpoint analysis showed a 
significant increasing trend for the adjusted standard incidence rate (ASIR) for both sexes (P-value<0.05). Annual 
percent changes (APC) for women and men were 18.7 and 19.9, respectively. The most common morphological 
blood cancers were ALL, ALM, MM and CLL which accounted for 60% of total hematopoietic system cancers. 
Joinpoint analyze showed a significant decreasing trend for ALM in both sexes (P-value<0.05). Conclusions: 
Hematopoietic system cancers in Iran demonstrate an increasing trend for incidence rate and decreasing trend 
for ALL, ALM and CLL morphology. 
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Although overall incidence is rare, leukemia is the most 
common type of childhood cancer. It accounts for 30% of 
all cancers diagnosed in children younger than 15 years 
(Belson et al., 2007), but it is not limited to children and 
has higher incidence among adults with more complicated 
treatment process (Tahmasebi et al., 2006).
Leukemia is classified to main four categories with 
different clinical symptoms: AML or acute myeloid 
leukemia which mostly involves adults and consists 
about 30% of total adults’ leukemia cases, ALL or acute 
lymphatic leukemia which is the most common type of 
disease among children and almost 80% of leukemia 
cases among children is attributed to this type and finally, 
CML or chronic myeloid leukemia which usually is seen 
among adults and CLL or chronic lymphatic leukemia 
the most common type of leukemia in adults which 90% 
of this type cases happens after 50 years old (Rodriguez-
Abreu et al., 2007). Also multiple myeloma or plasma cell 
myeloma is a malignant blood disease in which plasma 
cells (which produce anti body) involve by cancer (Raab 
et al.). Multiple myeloma consists less than 1% of total 
cancer cases and less than 10% of total cancer cases and 
10% of total blood malignancies and mostly involves old 
ones between 65-70 years old (Rodriguez-Abreu et al., 
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2007). Regarding increasing number of old age groups 
during past decades, multiple myeloma incidences have 
been increased (Rodriguez-Abreu et al., 2007).
According to United state statistics, leukemia 
incidence rate has been increased during 2002-2011 
(Howlader N NA, based on November 2013 SEER data 
submission, posted to the SEER web site, April 2014). 
Also an incidence increase has been observed in a twenty 
years period in Netherlands among women between 50-64 
years old (Van den Broek et al., 2012) and for Denmark 
between 1943-2003 (Thygesen et al., 2009).
In Iran, based on performed studies, blood malignancies 
have been surged during 1997-2003 for both sexes 
(Tahmasebi et al., 2006). Studies around the world show 
that blood malignancy incidence is increased by age 
(Coebergh et al., 2006; Sant et al., 2010; Dores et al., 2012; 
Novak et al., 2012). Performed studies in Iran confirm 
increasing trend of blood cancer incidence by age increase 
so that age groups higher than 70 years old has the most 
incidence rate (Tahmasebi et al., 2006). Studies in Iran 
and other countries have shown that blood malignancies 
incidence is higher among men than women (Tahmasebi 
et al., 2006; Sant et al., 2010; Zand et al., 2010; Dores 
et al., 2012; Novak et al., 2012; Howlader N NA, based 
on November 2013 SEER data submission, posted to the 
SEER web site, April 2014).
Although the etiology of leukemia is unknown, 
but some environmental factors such as ionizing 
radiations, chemical materials such as benzene, pesticides, 
chemotherapy, smoking, genetic disorders, family history 
about CLL, infection with HTLV-1, financial and social 
level have been recognized as the risk factors for blood 
cancer (Novak et al., 2012).
Some studies have confirmed changes in the 
Epidemiology and morphology trends of the cancers in 
some countries and Iran (Keyghobadi et al., 2014; Razi 
et al., 2014; Almasi et al., 2015; Mirzaei et al., 2015; 
Rafiemanesh et al., 2015). Considering different incidence 
rate around the world, so performed studies abroad the 
country cannot determine the cancer situation in Iran and 
also there has not been yet any study about epidemiology, 
morphology and trend of this important disease during 
recent years in Iran and on the other hand, epidemiological 
studies are necessary for successful planning, therefore 
this study was done to evaluate epidemiology and 
morphology of blood cancer during 2003-2008.
Materials and Methods
Data source
This is analytic cross-sectional study, carried out based 
on re-analysis national registry of cancer (NCR), and 
Disease Control and Prevention (CDC) report of ministry 
of Health and Medical Education in Iran. Deputy for 
health of each university is responsible for health issues 
of the population and all health activities are managed 
by these deputies. All deputies for health have been 
included in the NCR. Registrar would apply the national 
registration software which was developed by CDC. For 
pathologic centers, without software, the cancer records 
were gathered manually. The Cancer Office of CDC should 
provide techniques and funding supports. The data are 
transmitted every 3 months, by electronic file and also 
hard copy of ‘Cancer Registry Data Collection Form’; 
this form is comprised of three parts: part I, regarding 
patient’s identity characteristics in addition to the name 
of biopsy-taker physician, name of hospital, location of 
which the biopsy is taken, clinical diagnosis and date of 
biopsy sent to histological laboratory and demographic 
information of the patients includes race and residence. 
Part II includes the most important findings of patient’s 
clinical history. Part III includes preclinical findings. 
The information includes primary location of tumor, date 
of cancer diagnosis, morphology and histology and its 
behavior and diagnosis method. Physicians fill the form 
of clinical data and the official personnel fill the identity 
and demographic information. Quality control has been 
coordinated in five main areas by Cancer Office of CDC: 
Regarding completeness of coverage; ii) completeness 
of details; iii) accuracy of data; iv) accuracy of reports; 
v) accuracy of interpretation and vi) repeated cases are 
deleted from national data. Surveillance of pathology is 
based on the cancer record in several selected provinces 
to compare it with the present pathology cancer record 
for a general and complete evaluation and also for the 
accuracy of the collected data. IARC software provides 
a way to identify inaccuracies in data coding. Data were 
collected retrospectively reviewing all new hematopoietic 
and reticuloendothelial systems cancer patients in 
Cancer Registry Center report of health deputy for 
Iran during a 6-year period (2003 - 2008) (Bray et al., 
2012). Accordance of The International Classification of 
Diseases for Oncology (ICD-OC: topography with ICD-
OM: morphology) Hematopoietic and reticuloendothelial 
systems cancer was defined as ICD-O C42(Fritz, 2000). 
This study investigated all cases of the morphology 
of Acute Myeloid Leukemia (AML)(9861/3), Acute 
Lymphoblastic Leukemia, NOS (ALL)(9821/3), Chronic 
Lymphocytic Leukemia (CLL)(9823/3) and Multiple 
Myeloma(MM) (9732/3).
Statistical analysis
We calculated crude incidence rate (CIR) and the 
Age-standardized incidence rate (ASIR) per 100,000 
persons. We used direct standardized method using 
world standard population(Santos, 1999). To describe 
incidence time trends, we carried out joinpoint regression 
analysis using the software Joinpoint Regression Program, 
Version 4.1.1.1 October 2014. As well to evaluate the 
morphological changes, were obtained the percentage 
allocated for kind of morphological types. So to analysis 
morphology change percentage trends for six year, we 
carried out joinpoint regression analysis using the software 
Joinpoint Regression Program. The analysis included 
logarithmic transformation of the rates, maximum number 
of one joinpoints, and minimum of six years between 
zero joinpoints. All other program parameters were set 
to default values. The test of significance uses a Monte 
Carlo Permutation method (i.e., it finds “the best fit” line). 
joinpoint regression analysis involves fitting a series of 
joined straight lines on a log scale to the trends. The aim 
of the approach is to identify possible joinpoints where 
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a significant change in the trend occurs. In this study 0 
joinpiont (Full model) was a significant model. The final 
model selected was the most parsimonious of these, with 
the estimated annual percent change (APC) based on the 
trend within each segment. In describing trends, the terms 
“significant increase” or “significant decrease” signify 
that the slope of the trend was statistically significant (P 
< 0.05). All statistical tests were two sided.  
Results 
During studied years (2003-2008) totally 18353 cancer 
for hematopoietic and reticuloendothelial systems were 
recorded which 37.76% (6930 cases) related to women 
and 62.24% (11423 cases) were related to men. Sex ratio 
(male to female) is equal to 1.65 (table 1).
Morphological diversity for blood cancer cells is 
higher in men than women. Chi square test showed 
significant difference between sex and morphological type 
of blood cancer (P-Value<0.001).
Epidemiologic trend
Joinpoint analyze showed a significant increasing trend 
for adjusted standard incidence rate (ASIR) for both sexes. 
Annual percent change (APC) for women was 18.7 (CI: 
13.4 - 24.3) and for men equal to 19.9 (CI: 14.1 - 25.9) 
which can be seen in Figure1.
Morphological trend
The most common morphological blood cancer are 
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid 
Leukemia (AML), Multiple Myeloma (MM) and Chronic 
Lymphocytic Leukemia (CLL) which include 22.19%, 
15.66%, 11.39% and 10.09% of total hematopoietic 
system for women, respectively. These values for men 
are 21.14%, 12.24%, 13.11% and 14.36% for men, 
respectively.
It means that these 4 morphological types consist 60% 
and 60.84% of total hematopoietic system for women and 
men, respectively. (Table 2)
Joinpoint analyze shows a decreasing trend for ALL, 
Table 1. Frequency, Crude and age Standardized 
Incidence of Hematopoietic Systems Cancer by Sex, 
During the years 2003 to 2008
 Female Male
 N. CIR ASIR N. CIR ASIR
2003 677 2.09 2.43 1057 3.1 3.39
2004 946 2.87 3.26 1550 4.47 4.85
2005 1068 3.11 3.68 1728 4.78 5.36
2006 1263 3.7 4.44 2148 5.97 6.8
2007 1283 3.76 4.65 2240 6.22 7.36
2008 1693 4.96 6.29 2700 7.5 8.94
CIR: crude incidence rate (per 100,000 persons); ASIR: Age-standardized 
incidence rate (per 100,000 persons)
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Table 2. Frequency and percent Change in the percentage allocated to the four morphology data for hematopoietic 
systems cancer (2008-2003)
 2003 2004 2005 2006 2007 2008
  N % N % N % N % N % N %
Female ALL* 157 23.19 216 22.83 235 22 295 23.36 301 23.46 334 19.73
 AML 165 24.37 250 26.43 141 13.2 162 12.83 186 14.5 181 10.69
 MM 54 7.98 107 11.31 130 12.17 162 12.83 127 9.9 209 12.34
 CLL 75 11.08 103 10.89 121 11.33 122 9.66 106 8.26 172 10.16
Male ALL 220 20.81 418 26.97 347 20.08 500 23.28 459 20.49 471 17.44
 AML 209 19.77 270 17.42 191 11.05 206 9.59 270 12.05 252 9.33
 MM 97 9.18 200 12.9 223 13.31 271 12.99 291 14.6 287 13.48
 CLL 156 14.76 223 14.39 271 15.68 291 13.55 287 12.81 412 15.26
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL)
Table 3. Joinpoint Analyses of Cancers Percentage Allocated to the four Morphology Data for Hematopoietic 
Systems Cancer (2008-2003)
 Female Male
 APC 95% CI APC 95% CI
Acute Lymphoblastic Leukemia -1.9 -5.9 to 2.3 -4.4 -12.6 to 4.7
Acute Myeloid Leukemia -15.6^ -26.8 to -3.3 -13.3^ -23.2 to -2.1
Multiple Myeloma 5.4 -5.8 to 17.9 6.7 -1.5 to 15.5
Chronic Lymphocytic Leukemia -4 -10.2 to 2.7 -0.9 -6.2 to 4.6
^APC is significantly different from zero at alpha = 0.05
Figure 1. Hematopoietic systems cancer change trend 
for ASIR by sex group between 2003-2008
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AML and CLL types among both sex groups. Decreasing 
trends for ALM type with significant annual percent of 
change (APC) were equal to -15.63 and -13.32 for women 
and men, respectively (P-Value<0.05) (Table 3).
Discussion
According to obtained results, blood cancer in Iran 
has an increasing trend. During a study which was done 
by Tahmasebi et al. in Mazandaran province during 1996-
2003, an increasing trend for 8 years period was observed, 
with non-Hutchkin lymphoma as the highest incidence 
rate and myeloma leukemia has the lowest incidence rate 
(Tahmasebi et al., 2006). Farahmand et al. found during 
their study that standard incidence rate for blood cancer 
among children during a 8 years’ time period i.e. 2000-
2008 has been increased significantly for both sex groups 
and the highest incidence rate was related to ALL type 
(Farahmand et al., 2011).
Hejazi conducted a research in western Azerbaijan 
province in Iran for children less than 15 years old during 
2003-2008 showed that acute blood cancer incidence has 
not a regular decreasing or increasing trend during studied 
years (Hejazi et al., 2010). In a study which was done 
by Rajabli et al. from 2004-2009 in Golestan province, 
standardized incidence rate for leukemia among men 
and women were respectively 10.4 and 7.8 (per 100000 
population), respectively. Similar age standardized 
incidence rate for multiple myeloma among men and 
women were obtained equal to 2.1 and 2 (per 100000 
populations) which is higher than country and whole world 
(Rajabli et al., 2013).
Based on last data released by United States, leukemia 
incidence rate has been increased annually 0.2% from 
2002 to 2011 and attributed death toll has been decreased 
on average 1% from 2001 to 2010 (Howlader N NA, , 
based on November 2013 SEER data submission, posted 
to the SEER web site, April 2014). During a research 
which conducted in Korea from 1999-2008, blood cancer 
incidence has been raised from 10.2 to 13.7 and lymphatic 
myeloma and multiple myeloma were the most common 
types of malignant blood diseases (Park et al., 2012).
During a research which was done in Kazakhstan from 
2003-2012, blood cancer incidence has been decreased 
from 4.3 to 3.2 (Igissinov et al., 2014) and one study in 
Hong Kong showed a stable trend for blood cancer from 
1990- 2008 (Xie et al., 2012).
Also performed study in Croatia showed a significant 
ALL stable trend for ALL incidence rate from 1988- 2009, 
meanwhile AML incidence has been decreased and CML 
incidence showed decrease for female but it has been 
stable among male group. Also this study showed a stable 
incidence rate for ALL which is similar to England, USA 
and New Zealand. An increased incidence rate for CLL 
in Croatia is similar to Denmark and Netherlands (Novak 
et al., 2012).
Similar studies in USA concerning blood cancer in 
Europe and USA in 2005 showed that overall incidences 
for hematopoietic malignancies have been raised along 
western countries and AML incidence had slow decrease 
or stable trend in the most European countries but it has 
been surged in Wales and England about 70% from 1971 
for both sexes (Rodriguez-Abreu et al., 2007).
Also researches have shown that different blood cancer 
incidence are higher among men (than women) which is 
comparable in the countries including Iran, Kazakhstan, 
Croatia, European union and United states (Coebergh et 
al., 2006; Tahmasebi et al., 2006; Rodriguez-Abreu et 
al., 2007; Hejazi et al., 2010; Sant et al., 2010; Dastgiri 
et al., 2011; Farahmand et al., 2011; Modak et al., 2011; 
Smith et al., 2011; Dores et al., 2012; Novak et al., 2012; 
Rajabli et al., 2013) and higher incidence among men 
may be attributed to genetically or environmental factors 
(Rajabli et al., 2013; Igissinov et al., 2014).
Also this study showed that blood cancer incidence 
in Iran is being increased although some part of this 
increase may be attributed to improvements on cancer 
registry system, but there is the possibility for blood 
cancer increase due to increasing related risk factors and 
regarding the fact that etiology of disease is not known 
completely, so identification of risk factors for this 
disease around different parts of the country is essential 
for preventing and diagnosis at initial stages for better 
control over this disease.
Conclusion: It can conclude that the incidence of 
leukemia cancer is increasing in Iran. Therefore, the plan 
for the control and prevention of this disease must be a 
high priority for health policy makers. Our findings was 
obtained from the descriptive study on the incidence trend 
of the disease in recent years and it is recommended that 
analytical studies should be conducted to obtain a causal 
relationship and  solve problems related to the disease.
Limitations:It should be stated that the cancer registry 
system in Iran is still not fully and equally in all area and 
sometimes the differences in the quality and coverage of 
data is observed and in some cases there is Undercount 
and misclassification. 
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